LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $50.00.
Sam Slutsky has given his Buy rating due to a combination of factors related to Immunovant’s recent clinical trial results and market dynamics. The company presented promising topline data from its Phase 3 study of batoclimab for myasthenia gravis and a Phase 2b study for chronic inflammatory demyelinating polyneuropathy. These results indicate a clear dose response, suggesting that deeper IgG reductions could enhance treatment efficacy in several IgG-driven disorders.
Additionally, the study’s design, which focuses on intra-study comparisons, strengthens the evidence for the correlation between IgG lowering and clinical improvements. Despite some confusion around placebo response rates, the findings are thought-provoking and supportive of the drug’s potential. The observed dose/exposure response aligns with trends seen in other immune and inflammatory diseases, reinforcing confidence in the FcRn class’s therapeutic promise.
According to TipRanks, Slutsky is an analyst with an average return of -6.5% and a 31.25% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Astria Therapeutics, and Spyre Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $51.00 price target.